Skip to content

Efficacy of Teduglutide in the treatment of acute myocardial infarction: a prospective single-center randomized controlled study

Efficacy of Teduglutide in the treatment of acute myocardial infarction: a prospective single-center randomized controlled study

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2500095623
Enrollment
Unknown
Registered
2025-01-09
Start date
2025-03-01
Completion date
Unknown
Last updated
2025-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

acute myocardial infarction

Interventions

Control:control 0.05mg/kg/d subcutaneous injection
Teduglutide:Teduglutide 0.05mg/kg/d subcutaneous injection

Sponsors

The first affiliated hospital of anhui medical university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1.Age: 18-80 years old; 2.diagnosed with STEMI based on 2017ESC Guidlines for the management of acute myocardial infarction in patients presenting whith ST-segment elevation; 3.Myocardial infarction related chest pain occurred within 24 hours; 4.Wrriten informed consent was obtained form each patient upon enrollment;

Exclusion criteria

Exclusion criteria: 1.older patients (>80 years old); 2.being critically ill due to STEMI; 3.sustained ventricular tachycardia and ventricular fibrillation after STEMI; 4.patients with mechanical complications (including ventricular septal perforation, papillary muscle rupture and cardiac rupture); 5.severe cardiac shock with no reaction to vasopressors; 6.renal failure with estimated glomerular filtration<30ml/min/1.73m2; 7.acute infectious disease within 2 week before inclusion, chronic inflammatory disease, immunocompromised patients; 8.patients with neurological and psychiatric disorders; 9.patients with malignant tumors with a survival period of less than 1 year; 10.patients with liver failure; 11.patients allergic to the ingredients of the drug in this study; 12.pregnant or lactating women or women who may be considering pregnancy during the study period; 13.researchers determine any other circumstances in which patients are not suitable to participate in clinical trials;

Design outcomes

Primary

MeasureTime frame
Infarct size;microvascular obstruction volume;

Secondary

MeasureTime frame
cardiac function evaluation indicators;Major adverse cardiovascular and cerebrovascular events (MACCE events), including cardiovascular death, non fatal myocardial infarction, non fatal stroke, and ischemia driven revascularization;

Countries

China

Contacts

Public ContactXie Jun

The first affiliated hospital of anhui medical university

darcy_pann@hotmail.com+86 25 8310 6666

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026